Presentation is loading. Please wait.

Presentation is loading. Please wait.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Published byLorena Holland Modified over 5 years ago

Similar presentations

Presentation on theme: "Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients."— Presentation transcript:

1 Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients (A) and female patients (B). Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients (A) and female patients (B). There was no observed publication bias in the analysis of men (C) or women (D). Joseph A Pinto et al. ESMO Open 2018;3:e000344 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients."

Similar presentations

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.
Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)
Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
The decision tree with the two alternatives.

The decision tree with the two alternatives.
Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.
(A) Safety profile overview.

(A) Safety profile overview.
Detection rate for EGFR mutations in cfDNA.

Detection rate for EGFR mutations in cfDNA.
Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.

Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.
PRISMA study flow diagram

PRISMA study flow diagram

Similar presentations

Ads by Google